SciFi Futures
← Capabilities
Biotech & Medicine/Component technology

Safe heritable embryo genome editing

Editing a one-cell human embryo so that every cell of the resulting person carries the intended change and nothing else.

State of the art

Preclinical embryo and embryonic-stem-cell editing programs announced by Preventive (2025) and Origin Genomics (2026); mitochondrial donation by pronuclear transfer produced eight healthy babies in the UK (NEJM, 2025), the only sanctioned heritable-change clinical pathway.

What’s blocking it
  • Mosaicism - edits arrive after the first division, so cells of the same embryo differ
  • On-target large deletions, chromosome loss and chromothripsis occur in edited embryos and are invisible to biopsy-based testing
  • A biopsy of a few cells cannot certify the genome of the whole future person, so safety cannot be established before a birth

Who’s working on it

  • Public-benefit corporation announced October 2025 with about $30M - the largest known investment in heritable genome editing - to run preclinical safety research and publish even a negative answer

  • Lucas HarringtonResearcher
    Preventive

    Founder; did his PhD in Jennifer Doudna's lab and co-founded Mammoth Biosciences, and has committed publicly not to advance to clinical use if safety cannot be established

  • Shoukhrat MitalipovResearcher
    Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University

    Ran the first US human embryo-editing experiments (2017) and the nuclear-transfer oocyte work reported in 2025; consults for embryo-editing startups

  • Paula AmatoResearcher
    Oregon Health & Science University

    Reproductive endocrinologist on the US embryo-editing team and the one established scientist who agreed to advise Preventive (2025)

  • Dieter EgliResearcher
    Columbia University

    Studies what actually happens when a human embryo's DNA is cut, including the chromosome-loss and large-deletion failure modes that are the central safety obstacle

  • Fyodor UrnovResearcher
    Innovative Genomics Institute, University of California, Berkeley

    Leading gene-editing scientist and the field's most prominent critic of heritable editing, arguing in 2025 that these ventures should not proceed at all

What to invest in

KindInvestmentScale
researchWhole-genome single-cell validation methods on edited embryo models to quantify mosaicism and structural damage rates$$ $10M – $100M
policyInternational oversight and registry framework defining what preclinical evidence would ever justify a first clinical use$ < $10M

Sci-fi concepts in reach

Engineered human adaptation to other worldsgatingdirectGermline trait enhancementdirectNexus-6 androids (replicants)direct

Sources